EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?

Dimitris Kounatidis, Natalia Vallianou iD, Angelos Evangelopoulos, Ioannis Vlahodimitris, Eugenia Grivakou, Evangelia Kotsi, Krystalia Dimitriou, Alexandros Skourtis, Iordanis Mourouzis

Nutrients · 13.05.2023 · 15 (10) · 2294

DOI: 10.3390/nu15102294 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 13.05.2023. Verfasst von Dimitris Kounatidis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hippokration Hospital, 11572 Athens, Greece. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Nephropathies. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome in the kidney and the heart is increasingly being suggested to play a key role in mediating inflammation. In the kidney, NLRP3 activation was associated with the progression of diabetic kidney disease. In the heart, activation of the NLRP3 inflammasome was related to the enhanced release of interleukin-1β (IL-1β) and the subsequent induction of atherosclerosis and heart failure. Apart from their glucose-lowering effects, SGLT-2 inhibitors were documented to attenuate activation of the NLRP3, thus resulting in the constellation of an anti-inflammatory milieu. In this review, we focus on the interplay between SGLT-2 inhibitors and the inflammasome in the kidney, the heart and the neurons in the context of diabetes mellitus and its complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetic NephropathiesHumansInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinKidneyInterleukin-1beta

Stichwörter der Autor:innen

NLRP3SGLT-2 inhibitorscardioprotective effectsinflammasomeneuroprotective effectsreno-protective effects

Substanzen

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinSodium-Glucose Transporter 2 InhibitorsInterleukin-1beta

Autor:innen und Institutionen

  • Hippokration Hospital, 11572 Athens, Greece.
  • Evangelismos General Hospital, 10676 Athens, Greece.
  • Roche Diagnostics Hellas S.A., 15125 Athens, Greece.
  • Faculty of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

ORCID-Profile: Natalia Vallianou

Zitieren

APA

Kounatidis, D., Vallianou, N., Evangelopoulos, A., Vlahodimitris, I., Grivakou, E., Kotsi, E., Dimitriou, K., Skourtis, A., & Mourouzis, I. (2023). SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?. Nutrients, 15(10), 2294. https://doi.org/10.3390/nu15102294

Vancouver

Kounatidis D, Vallianou N, Evangelopoulos A, Vlahodimitris I, Grivakou E, Kotsi E, et al. SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?. Nutrients. 2023;15(10):2294. doi:10.3390/nu15102294

BibTeX
@article{Kounatidis2023,
  author = {Kounatidis, Dimitris and Vallianou, Natalia and Evangelopoulos, Angelos and Vlahodimitris, Ioannis and Grivakou, Eugenia and Kotsi, Evangelia and Dimitriou, Krystalia and Skourtis, Alexandros and Mourouzis, Iordanis},
  title = {SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?},
  journal = {Nutrients},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {2294},
  doi = {10.3390/nu15102294}
}
Kostenlos starten →